VIDEO: Highlights in psoriatic arthritis from ACR 2022

Editor’s note: This is a previously posted video, and the below is an automatically generated transcript to be used for informational purposes. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

We definitely have so much to talk about at these meetings, but I'll try to maybe drill down to some things that I found interesting in the ACR 2022 meeting. I think we are trying to get closer at personalized medicine for psoriatic arthritis. I think for a long time, we've been simply just borrowing whatever we learned from rheumatoid arthritis to psoriatic arthritis. But now, it is our time for psoriatic diseases. We've definitely better understood the different domains. So whether there's a more axial predominant or enthesitis predominant in our psoriatic arthritis patients, we are demanding more out of our clinical trials to try to find that right drug, for the right patient, at the right time. And there's just a lot more outcome measures to look at in some of these trials. Although, I would say that there probably wasn't any, you know, big randomized trial in this past ACR meeting, we do definitely, understand more about these mechanism of action, the different ones that we have, as well as the different domains that we have to treat, and that we understand that there are really nuances to these different PsA Phenotypes, and we can narrow down our choices now, with the patient in front of me. So there's a little bit less of this just, trial and error approach that we have, and we're really waiting a lot more on related conditions, such as an axial involvement or uveitis or IBD-related, and we're changing our treatments accordingly. So very exciting to see this. We obviously want more head-to-head trials, so that we can ultimately see the differences between these. And although, we do have a few in psoriatic arthritis, probably not as much as we have that we see in psoriasis only. But I think that this is something that we will see in the near future and will help us inform more, the differences between these mechanism of action, as well as the whole concept of switching within class, that we're learning more about. So as we know, we have, you know, five different TNF inhibitors. We have two different IL17 inhibitors. And you know, there's also a number of Jak inhibitors. So the question is, if you are not getting full, you know, response to one in a class is, you know, is there advantages to either switching a mechanism of action or just staying within class and just trying another one before you switch out of that class of medication? So I think there are a lots of new clinical trials that are looking at those, that I look forward to seeing, so that I can really take care of the patient that's in front of me.